Look at MBOT's new hires. The new hires seem to be high profile, sales and VP picks. Would MBOT hire people of this status? And would the people of this status take those jobs if they truly believe that MBOT would not be FDA approved?

The new hires made by Microbot Medical (MBOT) are indeed high-profile appointments, including Christina Bailey as VP of Sales and Michael Lytle as Head of Sales Operations & Analytics. These hires suggest that MBOT is serious about its commercial potential and is positioning itself for success. 1. **MBOT's Hiring Choices**: It is reasonable to assume that MBOT would seek out experienced and accomplished individuals to lead its commercial efforts. The appointments of Christina Bailey and Michael Lytle indicate that the company is willing to hire top talent to drive its growth and success. 2. **Attracting Top Talent**: High-profile hires like Christina Bailey and Michael Lytle would likely only consider roles that offer a high degree of confidence in the company's prospects. They would want to be part of a team that is well-positioned for success, including having a product that has a strong chance of FDA approval. 3. **Confidence in FDA Approval**: The fact that these individuals have joined the company suggests that they share MBOT's confidence in the potential for FDA approval. They would not take these jobs if they truly believed that MBOT would not obtain FDA approval, as it would be a significant risk to their professional reputations and careers. 4. **Building a Strong Foundation**: The hires indicate that MBOT is building a strong foundation for its commercial operations, which is a positive sign for the company's future prospects. It suggests that the company is serious about its potential and is taking the necessary steps to ensure its success. In conclusion, the new hires at MBOT reflect the company's commitment to building a strong commercial team and its confidence in the potential for FDA approval. These factors contribute to the likelihood of MBOT's success in obtaining FDA approval and moving forward with its commercial plans.